文献速递肿瘤 PET/CT

基于双时间点FDG PET Ki参数图的影像组学预测建模:用于淋巴瘤化疗反应预测

Radiomics predictive modeling from dual-time-point FDG PET Ki parametric maps: application to chemotherapy response in lymphoma.
PubMed 文献 · EJNMMI Res · 2023-07-26

研究分析了来自两个中心的45例淋巴瘤患者共126个病灶(化疗应答者75个、无应答者51个),从基线静态PET图像和双时间点Ki参数图提取影像组学特征。经ComBat协调后联合双时间点与静态特征的模型在测试集中取得AUC 0.97±0.02、准确率0.89±0.05、灵敏度0.92±0.09、特异度0.88±0.05,提示协调化及联合建模对预测淋巴瘤化疗反应有显著价值。

要点

  • 双时间点Ki参数图与静态影像组学特征联合并经ComBat协调后,预测化疗反应的测试集AUC为0.97±0.02。
  • 静态特征中GLRLM_RLNU与治疗反应强相关(AUC=0.75,p=0.0001,q=0.0007)。
  • 最具预测力的双时间点特征为GLCM_Energy、GLCM_Entropy和Uniformity,各自AUC=0.73、p=0.0001、q<0.0005。

核心结论

  • 结果表明影像组学特征的协调化以及联合双时间点与静态影像组学模型对预测淋巴瘤患者化疗反应具有显著价值。

研究设计与样本

  • 回顾性分析来自两个中心的45例接受化疗的淋巴瘤患者共126个病灶,其中应答病灶75个、无应答病灶51个。
  • 从基线静态PET图像和双时间点[18F]FDG PET代谢摄取率Ki参数图提取静态与双时间点影像组学特征。
  • 采用Spearman秩相关分析特征间相关性,单因素分析筛选特征后,使用最小冗余最大相关特征选择与XGBoost分类器进行多因素建模,并在ComBat协调前后分别构建模型。
  • 按80%/20%比例将患者数据集划分为训练/验证集与测试集,在测试集中报告AUC、灵敏度、特异度和准确率。

主要发现

  • 65个双时间点特征中有32个与部分静态特征呈可忽略至中等相关(ρ<0.7),其余33个特征呈高相关(ρ≥0.7)。
  • 单因素建模中,双时间点特征与静态特征的AUC之间未观察到显著差异。
  • 静态特征GLRLM_RLNU与治疗反应强相关(AUC=0.75,p值=0.0001,q值=0.0007)。
  • 最具预测力的双时间点特征为GLCM_Energy、GLCM_Entropy和Uniformity,各自AUC=0.73、p值=0.0001、q值<0.0005。
  • 多因素分析中,协调化后AUC均值范围增大;协调化联合双时间点与静态特征提供显著改善的预测(AUC=0.97±0.02、准确率=0.89±0.05、灵敏度=0.92±0.09、特异度=0.88±0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To investigate the use of dynamic radiomics features derived from dual-time-point (DTP-feature) [18F]FDG PET metabolic uptake rate Ki parametric maps to develop a predictive model for response to chemotherapy in lymphoma patients. METHODS: We analyzed 126 lesions from 45 lymphoma patients (responding n = 75 and non-responding n = 51) treated with chemotherapy from two different centers. Static and DTP radiomics features were extracted from baseline static PET images and DTP Ki parametric maps. Spearman's rank correlations were calculated between static and DTP features to identify features with potential additional information. We first employed univariate analysis to determine correlations between individual features, and subsequently utilized multivariate analysis to derive predictive models utilizing DTP and static radiomics features before and after ComBat harmonization. For multivariate modeling, we utilized both the minimum redundancy maximum relevance feature selection technique and the XGBoost classifier. To evaluate our model, we partitioned the patient datasets into training/validation and testing sets using an 80/20% split. Different metrics for classification including area under the curve (AUC), sensitivity (SEN), specificity (SPE), and accuracy (ACC) were reported in test sets. RESULTS: Via Spearman's rank correlations, there was negligible to moderate correlation between 32 out of 65 DTP features and some static features (ρ < 0.7); all the other 33 features showed high correlations (ρ ≥ 0.7). In univariate modeling, no significant difference between AUC of DTP and static features was observed. GLRLM_RLNU from static features demonstrated a strong correlation (AUC = 0.75, p value = 0.0001, q value = 0.0007) with therapy response. The most predictive DTP features were GLCM_Energy, GLCM_Entropy, and Uniformity, each with AUC = 0.73, p value = 0.0001, and q value < 0.0005. In multivariate analysis, the mean ranges of AUCs increased following harmonization. Use of harmonization plus combining DTP and static features was shown to provide significantly improved predictions (AUC = 0.97 ± 0.02, accuracy = 0.89 ± 0.05, sensitivity = 0.92 ± 0.09, and specificity = 0.88 ± 0.05). All models depicted significant performance in terms of AUC, ACC, SEN, and SPE (p < 0.05, Mann-Whitney test). CONCLUSIONS: Our results demonstrate significant value in harmonization of radiomics features as well as combining DTP and static radiomics models for predicting response to chemotherapy in lymphoma patients.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Samimi R, Shiri I, Ahmadyar Y, et al. Radiomics predictive modeling from dual-time-point FDG PET Ki parametric maps: application to chemotherapy response in lymphoma. EJNMMI Res. 2023. PMID: 37493872. doi:10.1186/s13550-023-01022-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。